Product Profiles: Allergic Rhinitis - Heavily genericized market sees areas of innovation

Datamonitor
June 23, 2011
146 Pages - SKU: DFMN6447621
License type:
Table of Contents Related Reports
Introduction

The allergic rhinitis market continues to see areas of innovation, as seen with the April 2011 FDA filing of Dymista (azelastine/fluticasone; Meda/Cipla). Within the immunotherapy class, novel therapies are making progress in the EU, and continuing to pursue development in the US. Amongst established symptomatic therapies, strategies are used to resist generic erosion.

Features and benefits
  • Access Datamonitor’s independent clinical and commercial assessment of marketed brands and key pipeline agents for allergic rhinitis.
  • Understand to what extent current and future therapies satisfy the main clinical unmet needs in allergic rhinitis.
  • Assessment of the strengths, weaknesses, opportunities, and threats for both symptomatic and immunotherapy treatments.
  • Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.
Highlights

The oral antihistamine class has seen an additional over-the-counter (OTC) shift, as the FDA approved Allegra (fexofenadine, Sanofi-Aventis) for OTC use in January 2011, which led to an OTC launch of the product in March 2011. This, and other methods of combating generic erosion, can be seen throughout the allergic rhinitis market.

In April 2011, Meda filed its fixed dose nasal antihistamine/corticosteroid combination Dymista (azelastine/fluticasone) with the FDA for the treatment of seasonal allergic rhinitis in patients aged 12 years and older. If approved, Dymista would be the first of its class to reach the market, addressing unmet needs in treating allergic rhinitis.

Movements have been seen in the allergen immunotherapy class; in January 2011 the FDA announced that it would lift the clinical hold that had been placed on Allergy Therapeutics’ Pollinex Quattro range in 2007. The sublingual tablet based grass allergens Grazax and Oralair continue to roll-out in the EU, and hope remains for their US approval.

Your key questions answered
  • How do marketed treatments of allergic rhinitis compare to one another and where will pipeline agents fit in?
  • What methods have been used to combat generic erosion post-patent expiry, and which are the most successful?
  • How do key opinion leaders differentiate between various treatments for allergic rhinitis?
  • What is the status of novel immunotherapy treatments for allergic rhinitis, and what is their commercial potential?
Please note: this is delivered as a Zip file.


 

Share this report


Other tasks

 
 

Research Assistance

Ask a question
 

Related Markets


Allergy/Immunology Reports

 
 

Free Alert Me service

Receive bi-weekly email alerts on new market research

Sign Up Today!